ToxSci Advance Access originally published online on July 26, 2006
Toxicological Sciences 2006 93(2):256-267; doi:10.1093/toxsci/kfl069
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kinetics of Elimination of Urinary Metabolites of Acrylamide in Humans
* RTI International, Research Triangle Park, North Carolina 27709; and UMDNJ, Newark, New Jersey 07103
Received February 23, 2006; accepted July 24, 2006
Acrylamide (AM), used in the manufacture of polyacrylamide and grouting agents, is produced during the cooking of foods. Workplace exposure to AM can occur through the dermal and inhalation routes. The objective of this study was to define the kinetics of elimination of AM and its metabolites following oral and dermal administration. This is the second part of a study in which metabolites and hemoglobin adducts of AM were determined in people (Fennell et al., 2005, Toxicol. Sci. 85, 447–459). (1,2,3-13C3)AM was administered in an aqueous solution orally (single dose of 0.5, 1.0, or 3.0 mg/kg) or dermally (three daily doses of 3.0 mg/kg) to sterile male volunteers. Urine samples were collected at 0–2, 2–4, 4–8, 8–16, and 16–24 h following administration orally, or at 0–2, 2–4, 4–8, 8–16, and 16–24 h following each of three daily dermal doses. 13C3-AM and its metabolites in urine, 13C3-glycidamide, 13C3-N-acetyl-S-(3-amino-3-oxopropyl)cysteine and its S-oxide, and 13C3-N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine, were quantitated using liquid chromatography-tandem mass spectrometry. The recovered urinary metabolites accounted for 45.6, 49.9, and 39.9% of a 0.5, 1.0, and 3.0 mg/kg oral dose (0–24 h), respectively, and for 4.5% of the dose after 3 mg/kg was administered daily for 3 days dermally (0–4 days). These results indicate that after oral administration AM is rapidly absorbed and eliminated. The half-life estimated for elimination of AM in urine was 3.1–3.5 h. After dermal administration, AM uptake is slow. This study indicated that skin provides a barrier that slows the absorption of AM, and results in limited systemic availability following dermal exposure to AM.
Key Words: acrylamide; glycidamide; NACP sulfoxide; urinary metabolites.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. I. Ghanayem, R. Bai, and L. T. Burka Effect of Dose Volume on the Toxicokinetics of Acrylamide and Its Metabolites and 2-Deoxy-D-glucose Drug Metab. Dispos., February 1, 2009; 37(2): 259 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Doroshyenko, U. Fuhr, D. Kunz, D. Frank, M. Kinzig, A. Jetter, Y. Reith, A. Lazar, D. Taubert, J. Kirchheiner, et al. In vivo Role of Cytochrome P450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 433 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bjellaas, P. T. Olesen, H. Frandsen, M. Haugen, L. H. Stolen, J. E. Paulsen, J. Alexander, E. Lundanes, and G. Becher Comparison of Estimated Dietary Intake of Acrylamide with Hemoglobin Adducts of Acrylamide and Glycidamide Toxicol. Sci., July 1, 2007; 98(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|